扶正祛瘀解毒方对晚期肠癌患者免疫功能的影响

Effect of Fuzheng Quyu Jiedu formula on the immune function of patients with advanced intestinal cancer

目的探讨扶正祛瘀解毒方对晚期肠癌患者免疫功能的影响。方法选取2021年1月—2023年月10月就诊于河北省中医院的晚期肠癌患者70例为研究对象,采用随机数字表法分为对照组和中药组,各35例。对照组采用mFOLFOX6方案化疗治疗,中药组采用mFOLFOX6方案化疗联合扶正祛瘀解毒方治疗。2组共治疗6个疗程(以14 d为1个疗程)。比较2组疗效、肿瘤标志物、血管生成因子、免疫功能相关指标水平、生活质量及不良反应。结果中药组治疗6个疗程后的临床受益率(CBR)较对照组更高(P<0.05)。2组治疗6个疗程后的血清肿瘤标志物[鞘糖脂抗原(CA50)、结肠癌特异性抗原-2(CCSA-2)、糖类抗原242(CA242)、癌胚抗原(CEA)]、血管生成因子[血+小板衍生生长因子(PDGF)、碱性成纤维细胞生长因子(bFGF)、血管内皮生长因子(VEGF)]水平及外周血CD8较治疗前降低,中药组较对照组更低(P<0.05);2组外周血CD4^(+)、CD3^(+)、CD4^(+)/CD8^(+)、自然杀伤细胞(NK)均升高,中药组较对照组更高(P<0.05)。2组治疗3、6个疗程后的卡氏功能状态评分量表(KPS)评分较治疗前升高,中药组较对照组更高(P<0.05)。中药组治疗期间的骨髓异常、恶心呕吐发生率较对照组更低(P<0.05)。结论扶正祛瘀解毒方可调节晚期肠癌患者肿瘤标志物、血管生成因子及免疫功能相关指标水平,抑制肿瘤进展,改善免疫功能,进而可提升患者生活质量和疗效,且具有较好的安全性。

Objective To explore the effect of Fuzheng Quyu Jiedu formula on the immune function of patients with advanced intestinal cancer.Methods 70 patients with advanced intestinal cancer admitted to Hebei Provincial Hospital of Traditional Chinese Medicine from January 2021 to October 2023 were selected as the research subjects,and they were divided into the control group and the traditional Chinese medicine group according to random number table method,with 35 cases in each group.The control group was treated with mFOLFOX6 regimen chemotherapy,and the traditional Chinese medicine group was treated with mFOLFOX6 regimen chemotherapy combined with Fuzheng Quyu Jiedu formula.Both groups were treated for a total of 6 courses of treatment(with 14 days as 1 course of treatment).The efficacy,the levels of tumor markers,angiogenic factors and immune function related indexes,quality of life,and adverse reactions were compared between two groups.Results The clinical benefit rate(CBR)of the traditional Chinese medicine group after 6 courses of treatment was higher than that of the control group(P<0.05).After 6 courses of treatment,compared with before treatment,serum levels of tumor markers[glycosphingolipid antigen(CA50),colon cancer-specific antigen-2(CCSA-2),carbohydrate antigen 242(CA242),carcinoembryonic antigen(CEA)],angiogenic factors[platelet-derived growth factor(PDGF),basic fibroblast growth factor(bFGF),vascular endothelial growth factor(VEGF)],+and peripheral blood CD8 decreased in both groups,and the traditional Chinese medicine group was lower than the control group(P<0.05);The levels of peripheral blood CD4^(+),CD3^(+),CD4^(+)/CD8^(+),and natural killer cells(NK)increased,and the traditional Chinese medicine group was higher than the control group(P<0.05).The scores of Karnofsky Performance Status(KPS)after 3 and 6 courses of treatment were higher in both groups compared with before treatment,and the traditional Chinese medicine group was higher than the control group(P<0.05).The incidence of bone marrow abnormality and nausea and vomiting in the traditional Chinese medicine group during treatment was lower than that in the control group(P<0.05).Conclusion Fuzheng Quyu Jiedu formula can regulate the levels of tumor markers,angiogenic factors and immune function related indexes in patients with advanced intestinal cancer.This therapy can inhibit tumor progression,improve immune function,and thus enhance quality of life of the patients and therapeutic effect.And this therapy has good safety.